Patients were randomized to receive either 1 week of triple therapy with LAN 30 mg BID , clarithromycin 500 mg BID , and tinidazole 500 mg BID , followed by 3 weeks of LAN 30 mg BID , or 2 weeks of dual therapy with RBC 400 mg BID plus clarithromycin 500 mg BID , followed by 2 weeks of RBC 400 mg BID .
